Weight LossClinical Trials
Survodutide
Also known as: BI 456906
A dual GLP-1/glucagon agonist with near 19% weight loss in Phase 3 trials, also targeting MASH liver disease.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~6–7 days
Typical Dose
4.8–6.0 mg weekly
Administration
Subcutaneous injection
Mechanism of Action
Combines GLP-1 appetite suppression with glucagon-mediated thermogenesis and hepatic fat mobilization for dual metabolic benefit.
Key Research Areas
weight lossGLP-1glucagonliverMASH
Frequently Asked Questions
What is Survodutide?▾
A dual GLP-1/glucagon agonist with near 19% weight loss in Phase 3 trials, also targeting MASH liver disease.
How does Survodutide work?▾
Combines GLP-1 appetite suppression with glucagon-mediated thermogenesis and hepatic fat mobilization for dual metabolic benefit.
What is the recommended dosage for Survodutide?▾
The typical research dosage is 4.8–6.0 mg weekly, administered via Subcutaneous injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Survodutide?▾
The half-life of Survodutide is approximately ~6–7 days. This affects dosing frequency and timing in research protocols.
Is Survodutide FDA approved?▾
Survodutide is currently classified as "Clinical Trials" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.
Research Disclaimer
The information provided about Survodutide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.